Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LAURUSLABS.NS
BuyPremium GrowerLaurus Labs Limited · Healthcare · India · $11.1B · Avg Vol: $61M/d
75
StockRankGet insider-trade alerts
Q
73
V
10
M
88
P/E (TTM)
95.7x
ROE
16.8%
D/E
0.5x
Dividend %
0.1%
COMPANY DESCRIPTION
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.1B | 50.0B | 55.1B | 67.2B | 3.8% | 72.9B | 82.3B | 94.2B | 18.4% |
| EPS (INR) | 14.69 | 2.98 | 6.65 | 16.47 | 3.9% | 20.32 | 25.28 | 28.98 | 32.6% |
| Shares | 538.7M | 539.0M | 539.3M | 539.9M | +0.2% | 540.3M | — | — | — |
| Debt | 20.2B | 25.8B | 27.6B | 25.2B | 7.7% | 25.3B | — | — | — |
| Equity | 40.4B | 41.1B | 44.7B | 53.0B | 9.5% | — | — | — | — |
| Op CF | 9.9B | 6.7B | 6.0B | 16.2B | 17.8% | 16.3B | — | — | — |
| Inv CF | -10.0B | -8.2B | -6.8B | -10.9B | — | — | — | — | — |
| Fin CF | -266.4M | 2.5B | 392.8M | -5.2B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+8.7%
SMA 50SMA 200
Close
$20.30
RSI (14)
66.3
52W High
$20.49
From 52W High
1.0%
SCORE BREAKDOWN
Quality
73
ROIC
19.5%89.8
ROE
16.8%84.7
GP/Assets
41.1%79.3
Op. Margin
25.4%88.7
FCF/Assets
5.3%71.3
Piotroski
894.2
Int. Cover
8.3x59.1
D/E Ratio
0.46x30.5
Current Ratio
1.33x20.9
Value
10
P/E (TTM)
95.7x9.6
EV/EBITDA
52.7x11.0
P/FCF
190.6x8.7
P/B
19.7x5.8
P/S
14.4x20.4
Div Yield
0.1%2.4
Momentum
88
52W High %
99%99.2
RS 6M
91%96.0
SMA 50/200
1.35x95.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+43%50.6
Q Growth
125%86.9
FUNDAMENTALS
Market Cap
$11.1B
P/E (Forward)
66.9x
Gross Margin
59.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LAURUSLABS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LAURUSLABS.NS | Laurus Labs Limited(you) | $11.1B | 75 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
| DIVISLAB.NS | Divi's Laboratories Limited | $26.8B | 73 | Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%